Cover Image
Market Research Report

U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management

Published by Medtech Insight Product code 204529
Published Content info 192 Pages
Delivery time: 1-2 business days
Price
Back to Top
U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management
Published: June 1, 2014 Content info: 192 Pages
Description

Pain is the single most common reason patients seek medical care, accounting for approximately half of all physician office visits in the United States (U.S.); some studies suggest that more than one-third of people in the U.S. suffer from a chronic pain condition at some point in their lives.

This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).

During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.

Table of Contents
Product Code: A374

Table of Contents

EXECUTIVE SUMMARY

  • i. Pain Management Pharmaceuticals
    • a. Nonprescription Analgesics and Anesthetics
      • i. Nonprescription Systemic Analgesics
      • ii. Nonprescription Topical Analgesics
      • iii. Market Forecast
    • b. Prescription Analgesics and Anesthetics
      • i. Prescription Non-Steroidal Anti-Inflammatory Drugs
      • ii. Opioid Analgesics
      • iii. Opioid/Nonopioid Combination Analgesics
      • iv. Antimigraine Analgesics
      • v. Adjuvant Analgesics
      • vi. General, Regional, and Local Anesthetics
      • vii.. Market Forecast
    • c. Combined Market Forecast
      • ii. Pain Management Devices
    • a. Electrical Stimulators
      • i. Transcutaneous Electrical Nerve Stimulators
      • ii. Neurostimulators
      • iii. Market Forecast
    • b. Analgesia Infusion Pumps
      • i. Implantable Analgesia Infusion Pumps
      • ii. External Analgesia Infusion Pumps
      • iii. Market Forecast
    • c. Combined Market Forecast
      • iii. Combined Market Forecast
  • Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018

1. PAIN MANAGEMENT OVERVIEW

  • 1.1. Pain Physiology
    • 1.1.1. The Nervous System
    • 1.1.2. Pain Perception
    • 1.1.3. Pain Classification
      • 1.1.3.1. Nociceptive Pain
      • 1.1.3.2. Non-Nociceptive Pain
      • 1.1.3.3. Acute Pain
      • 1.1.3.4. Chronic Pain
  • 1.2. Pain Assessment Techniques
  • 1.3. Pain Prevalence
  • 1.4. Common Pain Syndromes
    • 1.4.1. Arthritis Pain
    • 1.4.2. Back Pain
    • 1.4.3. Burn Pain
    • 1.4.4. Cancer Pain
    • 1.4.5. Headache Pain
    • 1.4.6. Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain
    • 1.4.7. Obstetric Pain
    • 1.4.8. Podiatric Pain
    • 1.4.9. Sciatic Pain
    • 1.4.10. Temporomandibular Pain
    • 1.4.11. Trauma Pain
  • 1.5. Clinical Approaches to Pain Management
    • 1.5.1. Pain Management Guidelines
    • 1.5.2. Pain Management Guidelines for Older Adults
    • 1.5.3. Interventional Pain Management Guidelines
    • 1.5.4. Pain Management Options
      • 1.5.4.1. Pharmaceutical Options
      • 1.5.4.2. Device-Based Options
      • 1.5.4.3. Alternative Therapy Options
  • Exhibit 1-1: Common Causes of Neuropathic Pain
  • Exhibit 1-2: United States Population, by Selected Ages, 1990-2050
  • Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management

2. PAIN MANAGEMENT PHARMACEUTICALS

  • 2.1. Pharmaceutical Formulations and Drug Delivery
    • 2.1.1. Oral Drug Delivery
    • 2.1.2. Injection/Infusion Drug Delivery
      • 2.1.2.1. Injection
        • 2.1.2.1.1. Intramuscular Injection
        • 2.1.2.1.2. Subcutaneous Injection
      • 2.1.2.2. Infusion
        • 2.1.2.2.1. Intravenous Infusion
        • 2.1.2.2.2. Intraspinal Infusion
        • 2.1.2.2.3. Intraoperative Site Infusion
    • 2.1.3. Inhalation Drug Delivery
    • 2.1.4. Transdermal Drug Delivery
    • 2.1.5. Transmucosal Drug Delivery
    • 2.1.6. Nonsteroidal Anti-Inflammatory Drugs
      • 2.1.6.1. Heart Attack and Hypertension Risks
      • 2.1.6.2. The Food and Drug Administration and Labeling
      • 2.1.6.3. Naproxen Risks
  • 2.2. The Benefits of Aspirin
    • 2.2.1. Aspirin and Heart Attack/Stroke Prevention
    • 2.2.2. Aspirin and Heart Failure
    • 2.2.3. Aspirin and Cancer Prevention
  • 2.3. Market Analysis
    • 2.3.1. Nonprescription Analgesics and Anesthetics
      • 2.3.1.1. Market Forecast
      • 2.3.1.2. Nonprescription Systemic Analgesics
        • 2.3.1.2.1. Acetaminophen
        • 2.3.1.2.2. Nonprescription Nonsteroidal Anti-Inflammatory Drugs
        • 2.3.1.2.3. Market Forecast
        • 2.3.1.2.4. Competitive Analysis
    • 2.3.1.3. Nonprescription Topical Analgesics and Anesthetics
      • 2.3.1.3.1. Amino Amides and Esters
      • 2.3.1.3.2. Capsaicin
      • 2.3.1.3.3. Methyl and Trolamine Salicylates
      • 2.3.1.3.4. Topical Patches
      • 2.3.1.3.5. Market Forecast
      • 2.3.1.3.6. Competitive Analysis
    • 2.3.2. Prescription Analgesics and Anesthetics
      • 2.3.2.1. Market Forecast
      • 2.3.2.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
        • 2.3.2.2.1. Acetic Acid Derivatives
        • 2.3.2.2.2. Anthranilic Acid Derivatives
        • 2.3.2.2.3. Cyclooxygenase-2 Selective Inhibitors
        • 2.3.2.2.4. Enolic Acid Derivatives
        • 2.3.2.2.5. Propionic Acid Derivatives
        • 2.3.2.2.6. Salicylic Acid Derivatives
        • 2.3.2.2.7. Market Forecast
        • 2.3.2.2.8. Competitive Analysis
      • 2.3.2.3. Opioid Analgesics
        • 2.3.2.3.1. Buprenorphine
        • 2.3.2.3.2. Butorphanol
        • 2.3.2.3.3. Codeine
        • 2.3.2.3.4. Fentanyl
        • 2.3.2.3.5. Hydromorphone
        • 2.3.2.3.6. Levorphanol
        • 2.3.2.3.7. Meperidine
        • 2.3.2.3.8. Morphine
        • 2.3.2.3.9. Nalbuphine
        • 2.3.2.3.10. Oxycodone
        • 2.3.2.3.11. Oxymorphone
        • 2.3.2.3.12. Pentazocine
        • 2.3.2.3.13. Propoxyphene
        • 2.3.2.3.14. Remifentanil
        • 2.3.2.3.15. Tramadol
        • 2.3.2.3.16. Tapentadol
        • 2.3.2.3.17. Hydrocodone
        • 2.3.2.3.18. Market Forecast
        • 2.3.2.3.19. Competitive Analysis
      • 2.3.2.4. Opioid/Nonopioid Combination Analgesics
        • 2.3.2.4.1. Market Forecast
        • 2.3.2.4.2. Competitive Analysis
      • 2.3.2.5. Antimigraine Analgesics
        • 2.3.2.5.1. Diclofenac
        • 2.3.2.5.2. Dihydroergotamine
        • 2.3.2.5.3. Divalproex Sodium
        • 2.3.2.5.4. Triptans
        • 2.3.2.5.5. Market Forecast
        • 2.3.2.5.6. Competitive Analysis
      • 2.3.2.6. Adjuvant Analgesics
        • 2.3.2.6.1. Anticonvulsants
        • 2.3.2.6.2. Antidepressants
        • 2.3.2.6.3. Corticosteriods
        • 2.3.2.6.4. Market Forecast
        • 2.3.2.6.5. Competitive Analysis
      • 2.3.2.7. General, Regional, and Local Anesthetics
        • 2.3.2.7.1. Inhalation General Anesthetics
        • 2.3.2.7.2. Intravenous General Anesthetics
        • 2.3.2.7.3. Anesthetics Used in Balanced Anesthesia
        • 2.3.2.7.4. Regional/Local Anesthetics
        • 2.3.2.7.5. Market Forecast
        • 2.3.2.7.6. Competitive Analysis
    • 2.3.3. Combined Market Forecast
  • Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods
  • Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics
  • Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics
  • Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018
  • Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier
  • Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier
  • Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018
  • Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier
  • Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier
  • Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier
  • Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier
  • Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier
  • Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018

3. PAIN MANAGEMENT DEVICES

  • 3.1. Electrical Stimulators
    • 3.1.1. Transcutaneous Electrical Nerve Stimulators
      • 3.1.1.1. Market Forecast
      • 3.1.1.2. Competitive Analysis
    • 3.1.2. Neurostimulators
      • 3.1.2.1. Occipital Nerve Stimulation
      • 3.1.2.2. Neuromuscular Stimulators
      • 3.1.2.3. Spinal Cord and Peripheral Nerve Stimulators
      • 3.1.2.4. Market Forecast
      • 3.1.2.6. Competitive Analysis
  • 3.2. Analgesia Infusion Pumps
    • 3.2.1. Implantable Analgesia Infusion Pumps
      • 3.2.1.1. Market Forecast
      • 3.2.1.2. Competitive Analysis
    • 3.2.2. External Analgesia Infusion Pumps
      • 3.2.2.1. Nerve Block
      • 3.2.2.2. Patient-Controlled Analgesia Infusion Pumps
      • 3.2.2.3. Products
      • 3.2.2.4. Market Forecast
      • 3.2.2.5. Competitive Analysis
  • 3.3. Combined Market Forecast
  • Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder
  • Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy
  • Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018
  • Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
  • Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018
  • Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier
  • Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier
  • Exhibit 3-8: Implantable Analgesia Infusion Pumps, Market Forecast, 2013-2018
  • Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier
  • Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018
  • Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier
  • Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018

4. COMPANY PROFILES

  • 4.1. AstraZeneca PLC
  • 4.2. Baxter Healthcare, Inc./Baxter International, Inc.
  • 4.3. Bayer HealthCare AG/Bayer AG
  • 4.4. Boston Scientific Corporation
  • 4.5. CareFusion Corporation
  • 4.6. Chattem, Inc./sanofi-aventis LLC
  • 4.7. DJO Global, Inc.
  • 4.8. Eli Lilly and Company
  • 4.9. Endo Pharmaceutical Holdings, Inc./Endo International PLC
  • 4.10. GlaxoSmithKline PLC
  • 4.11. Hospira, Inc.
  • 4.12. International Rehabilitative Sciences, Inc., d/b/a RS Medical
  • 4.13. Johnson & Johnson
  • 4.14. Medtronic, Inc.
  • 4.15. Pfizer, Inc.
  • 4.16. Purdue Pharma LP
  • 4.17. Teva Pharmaceutical Industries LTD

APPENDIX: COMPANY LISTING

Back to Top